Scholar Rock's stock soars more than 315% on positive trial of treatment for spinal muscular atrophy
Scholar Rock Holding Corp.'s stock soared more than 315% Monday to put it on track for its biggest ever one-day gain, after the clinical-stage biotech company said a late-stage trial of a treatment ...
"Our preliminary findings show that German children with SMA, despite significant physical disability, have surprisingly good subjective HRQoL." – Erik Landfeldt, MSc, PhD Previous studies have found ...
Spinal muscular atrophy is a debilitating genetic condition that’s usually fatal by a few years of age. But an intriguing case study might demonstrate a simple new treatment, with a child showing no ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new long-term data for Evrysdi ® (risdiplam) in a broad range of ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Topline results from a phase 3 clinical trial showed an ...
The risk of scoliosis was largely related to what type of SMA a patient had, with those with type III having the lowest risk and those with type II developing scoliosis at a later age than those with ...
With the intensification of global population aging, muscle atrophy, characterized by the loss of muscle mass and function, has become an important health issue affecting the elderly. Researchers have ...
Muscle atrophy is a primary characteristic of both sarcopenia and cachexia, significantly impacting physical function and quality of life. This figure illustrates the multifaceted causes of muscle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback